Metastasis causes a majority of deaths in breast cancer patients. Metastasis is the spread of cancer to distant sites in the body away from the primary tumor, creating secondary tumors, or metastases. A tumor metastasizes when cancer cells strategically regulate genes that play a role in angiogenesis, epithelial-mesenchymal transition (EMT), migration, invasion, and regulation of the cell cycle to bypass apoptosis and increase proliferation and stemness. Several transcription factors have also been identified to play a role in metastatic breast cancer, as they enable invasion, intravasation, transport, extravasation, and colonization of metastasis through other processes such as angiogenesis and EMT, making them a prime target for cancer treatment. Understanding how transcription factors play a role in breast cancer metastasis will enable the development of targeted therapeutics for breast cancer. This paper reviews the roles of E2Fs, hypoxia-inducible factors (HIFs), EMT master regulators, sex determining region Y (SRY)-related high-mobility group (HMG) box (SOX), E26 transformation-specific (ETS), Yin Yang 1 (YY1), forkhead box M1 (FoxM1), BTB domain and CNC homology 1 (Bach1), sineoculis homeobox homolog (SIX), runt-related transcription factor 2 (RUNX2), myelocytomatosis (MYC), Kruppel-like factors (KLFs), and c-Jun in breast cancer metastasis.

Molluscum contagiosum (MC) is a common skin infection caused by a poxvirus, primarily affecting children and immunocompromised adults. It manifests as single or multiple raised, pearl-like papules and is highly contagious, spreading through skin contact or contaminated objects. Traditional treatments include cryosurgery, curettage, and pulsed dye laser ablation. However, in early 2024, berdazimer topical gel, 10.3% (ZELSUVMI^TM), was approved as the first topical treatment for MC. This review explores the potential of Zelsuvmi gel as a significant advancement in treatment due to its nitric oxide (NO)-producing properties. NO is a naturally occurring molecule in the body with multiple roles, including immune defense, antimicrobial activity, and modulation of apoptosis, inflammation, and cytokine production. The novel mechanism of action of Zelsuvmi, utilizing NO’s antiviral properties, has demonstrated compelling efficacy in clinical settings. The article also considers the broader implications of this treatment, not only for current dermatological practice but also for future research into innovative therapies for viral skin infections. Through an evaluation of clinical data, this review highlights Zelsuvmi’s potential to transform treatment approaches for MC, offering a non-invasive, effective option that may influence both clinical management and future prevention strategies.

Immediate implant-supported rehabilitation of atrophic maxillae with a fixed screw-retained prosthesis has to deal with the fixtures’ disparallelism and a high risk of fracture of the fixture-abutment connecting screw. After the flapless placement of six implants, with the distal ones inclined at more than 30° to bypass the sinus cavities and reduce the cantilever effects, the provisional prosthesis was immediately connected. The low-profile OT Equator attachment system enabled a trustworthy anchorage of the superstructure without the connection-screws allocation on the rear fixtures. Three months later, all implants were definitively loaded. The patient was monitored for two years follow-up. No problem arose during the whole treatment. The prosthesis maintained its stability and anchorage with complete functional and aesthetic results. No signs of periimplantitis or radiographically evident bone loss were noted. The OT Bridge system successfully simplified the immediate loading of all implants regardless of the inclination of the rear fixtures, avoiding a provisional mobile denture.

Hypertension (HTN) is connected to many complications such as stroke, heart attack, heart failure, and kidney damage. Aging, lifestyle modifications, and obesity are risk factors associated with arterial HTN. On the other hand, chronic kidney disease (CKD) is a gradually progressive disease that is associated with cardiovascular disease (CVD), HTN, anemia, electrolyte imbalance, acid-base abnormalities, and bone disease. Blood pressure (BP) in hemodialysis patients shows a dynamic nature during dialysis procedures, including intradialytic hypotension and/or intradialytic HTN. Even though hypotensive events are common in hemodialysis sessions, intradialytic HTN, in which the BP increases during and/or immediately after hemodialysis, was associated with a higher mortality risk. The prevalence of intradialytic HTN has been described in 5–20% of hemodialysis treatments. The coexisting comorbidities in CKD patients need adequate pharmacological treatment. As a result, CKD patients are at a high risk for polypharmacy, which causes an elevated risk for adverse drug effects and influences non-adherence to medication. In addition, it is required individualization of medication doses adapted to the decreased renal function according to the progression of CKD. The improvement of health literacy through suitable interventions can facilitate the perception of illness, resulting in high therapy adherence in such a group of patients. This review considers the aspects of HTN management and adherence to the treatment in patients in permanent hemodialysis therapy, contributing to the determination of more effective strategies for improved treatment compliance, aiming at the prevention of CVD in this patient population.

Combined treatment of photobiomodulation therapy and pilocarpine hydrochloride (Salagen) helped a patient suffering from severe oral mucositis and malnutrition resulting from radiochemotherapy for head and neck cancers. This treatment sped up the patient’s healing process and improved his quality of life by stimulating cells and increasing saliva secretion. The severity of oral mucositis was measured according to the World Health Organization (WHO) scale and the oral mucositis assessment scale. This case report highlighted a new combination treatment that may be the key to successfully managing severe oral mucositis during radiochemotherapy without the need to stop or modify cancer therapy.